Effect of AMPK/mTOR/S6K1 pathways and the insulin-sensitizing effect for adiponectin in endometrial cancer cells
- Author:
- No author available
- Journal Title:
- Chinese Journal of Obstetrics and Gynecology
- Issue:
- 8
- DOI:
- 10.3760/cma.j.issn.0529-567x.2018.08.008
- Key Word:
- 子宫内膜肿瘤;脂联素;AMP活化蛋白激酶类;TOR丝氨酸-苏氨酸激酶;核糖体蛋白质S6激酶类;胰岛素抗药性
Abstract： 目的 探讨脂联素对子宫内膜癌HEC-1B细胞腺苷酸活化蛋白激酶(AMPK)/哺乳类雷帕霉素靶蛋白(mTOR)/核糖体蛋白S6激酶1(S6K1)信号通路及胰岛素增敏效应的影响.方法 实验分为4组:脂联素组(Ad组,加入20μg/ml的脂联素作用30 min);抑制剂组(加入10μmol/L的AMPK抑制剂——复合物C作用30 min);脂联素+抑制剂组(Ad+抑制剂组,10μmol/L复合物C预处理30 min后,再加入20μg/ml脂联素作用30 min);对照组(仅加入无血清DMEM培养基).(1)荧光定量PCR技术及蛋白印迹法检测HEC-1B细胞中脂联素受体(AdipoR)1、AdipoR2 mRNA和蛋白的表达水平.(2)以不同浓度(分别为2.5、5、10、20μg/ml)脂联素作用于HEC-1B细胞30 min,增敏实验时再加50 nmol/L胰岛素作用5 min;以20μg/ml脂联素作用于HEC-1B细胞不同时间(分别为15、30、45、60 min),增敏实验时再加50 nmol/L胰岛素作用5 min.蛋白印迹法检测HEC-1B细胞中AMPK、mTOR、S6K1蛋白活化水平以及胰岛素受体底物1(IRS1)酪氨酸磷酸化水平.(3)活细胞计数(CCK-8)法检测4组HEC-1B细胞的增殖能力,体外穿膜实验检测4组HEC-1B细胞的迁移能力.结果 (1)在HEC-1B细胞中,AdipoR1 mRNA及蛋白的表达水平分别为8.50±0.09、0.91±0.03,明显高于AdipoR2 mRNA及蛋白(分别为1.00±0.00、0.69±0.03;P<0.05).(2)脂联素以时间、浓度依赖方式诱导HEC-1B细胞中AMPK蛋白活化水平增高但抑制mTOR、S6K1蛋白活化水平(P<0.05),且脂联素浓度为20μg/ml、作用时间为30 min时,AMPK蛋白的活化水平均达到峰值.脂联素以浓度依赖方式诱导IRS1酪氨酸磷酸化水平增高(P<0.05).(3)Ad组HEC-1B细胞增殖的抑制率为(0.68±0.34)％,Ad+抑制剂组为(0.24±0.04)％,两组比较,差异有统计学意义(t=17.88,P<0.05).Ad组穿膜细胞数为(77±8)个,Ad+抑制剂组为(132±13)个,两组比较,差异有统计学意义(t=-7.34,P<0.05).结论 脂联素通过AMPK/mTOR/S6K1信号通路发挥抑制子宫内膜癌HEC-1B细胞增殖的效应,并通过调控AMPK/S6K1/IRS1信号通路增加HEC-1B细胞对胰岛素的敏感性.
- [1]Maria Moreno-Navarrete, Jose,Ortega, Francisco,Angel Sanchez-Garrido, Miguel,etc.Phosphorylated S6K1 (Thr389) is a molecular adipose tissue marker of altered glucose tolerance[J].2013,24(1).
- [2]Fangxin, Zeng,Jinyu, Shi,Yang, Long,etc.Adiponectin and Endometrial Cancer: A Systematic Review and Meta-Analysis.[J].2015,36(4).
- [3]Kimura N,Witters LA,Richardson C,etc.A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway.[J].2003,8(1).
- [4]Wanwan, Sun,Jieli, Lu,Shengli, Wu,etc.Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women.[J].2016,(10).
- [5]Liu F,Wang L,Liu M,etc.Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1.[J].2007,282(11).
- [6]González,F..Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunction[J].2012,77(4).
- [7]Maryam, Esfahani,Ahmad, Movahedian,Mostafa, Baranchi,etc.Adiponectin: an adipokine with protective features against metabolic syndrome.[J].2015,18(5).
- [8]Zhang, Lizhi,Wen, Ke,Han, Xinxin,etc.Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway[J].2015,137(2).
- [9]Saha AK,Nawrocki AR,Rajala MW,etc.Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists.[J].2006,281(5).
- [10]Nagaraju, Ganji Purnachandra,Rajitha, Balney,Aliya, Sheik,etc.The role of adiponectin in obesity-associated female-specific carcinogenesis[J].2016,31.
- [11]Ersilia, Nigro,Olga, Scudiero,Maria Ludovica, Monaco,etc.New insight into adiponectin role in obesity and obesity-related diseases.[J].2014,2014.